Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Penumbra, Inc is a medical devices business based in the US. Penumbra shares (PEN) are listed on the NYSE and all prices are listed in US Dollars. Penumbra employs 3,300 staff and has a trailing 12-month revenue of around USD$560.4 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced investors
52-week range | USD$121.8 - USD$314.22 |
---|---|
50-day moving average | USD$261.5842 |
200-day moving average | USD$226.1342 |
Wall St. target price | USD$310 |
PE ratio | 813.7931 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$0.303 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Penumbra stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Penumbra's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Penumbra's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 814x. In other words, Penumbra shares trade at around 814x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Penumbra's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$18.5 million.
The EBITDA is a measure of a Penumbra's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | USD$560.4 million |
---|---|
Gross profit TTM | USD$356.6 million |
Return on assets TTM | -1.51% |
Return on equity TTM | -3.43% |
Profit margin | -2.8% |
Book value | $17.616 |
Market capitalisation | USD$10.3 billion |
TTM: trailing 12 months
There are currently 3.3 million Penumbra shares held short by investors – that's known as Penumbra's "short interest". This figure is 45.1% down from 6.1 million last month.
There are a few different ways that this level of interest in shorting Penumbra shares can be evaluated.
Penumbra's "short interest ratio" (SIR) is the quantity of Penumbra shares currently shorted divided by the average quantity of Penumbra shares traded daily (recently around 665708.01603206). Penumbra's SIR currently stands at 4.99. In other words for every 100,000 Penumbra shares traded daily on the market, roughly 4990 shares are currently held short.
However Penumbra's short interest can also be evaluated against the total number of Penumbra shares, or, against the total number of tradable Penumbra shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Penumbra's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Penumbra shares in existence, roughly 90 shares are currently held short) or 0.1154% of the tradable shares (for every 100,000 tradable Penumbra shares, roughly 115 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Penumbra.
Find out more about how you can short Penumbra stock.
We're not expecting Penumbra to pay a dividend over the next 12 months.
Penumbra's shares were split on a 10:1 basis on 16 November 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Penumbra shares – just the quantity. However, indirectly, the new 90% lower share price could have impacted the market appetite for Penumbra shares which in turn could have impacted Penumbra's share price.
Over the last 12 months, Penumbra's shares have ranged in value from as little as $121.8 up to $314.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Penumbra's is 0.2273. This would suggest that Penumbra's shares are less volatile than average (for this exchange).
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; rehabilitation tools that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.